$ACUT
Accustem Sciences Inc.

2024 Q3 Form 10-Q Financial Statement

#000149315224036330 Filed on September 16, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $235.6K
YoY Change -34.06%
% of Gross Profit
Research & Development $31.41K $41.75K
YoY Change 57.43% 186.42%
% of Gross Profit
Depreciation & Amortization $907.00 $907.00
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $328.2K $278.2K
YoY Change -45.17% -25.36%
Operating Profit -$328.2K -$278.2K
YoY Change -45.17% -25.36%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$328.2K -$278.2K
YoY Change -45.17% -25.36%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$328.2K -$278.2K
YoY Change -45.17% -25.36%
Net Earnings / Revenue
Basic Earnings Per Share -$0.03 -$0.02
Diluted Earnings Per Share -$0.03 -$0.02
COMMON SHARES
Basic Shares Outstanding 11.35M shares 11.35M shares
Diluted Shares Outstanding 11.35M shares 11.35M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.07K
YoY Change -61.82%
Cash & Equivalents $37.08K $46.07K
Short-Term Investments
Other Short-Term Assets $91.36K
YoY Change
Inventory
Prepaid Expenses $65.41K $91.36K
Receivables
Other Receivables
Total Short-Term Assets $102.5K $137.4K
YoY Change -59.43% -69.64%
LONG-TERM ASSETS
Property, Plant & Equipment $1.325K $2.233K
YoY Change -73.26% -61.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.325K $2.233K
YoY Change -73.26% -61.91%
TOTAL ASSETS
Total Short-Term Assets $102.5K $137.4K
Total Long-Term Assets $1.325K $2.233K
Total Assets $103.8K $139.7K
YoY Change -59.69% -69.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $790.2K $744.7K
YoY Change 82.77% 94.55%
Accrued Expenses $164.1K $154.9K
YoY Change -64.76% -58.31%
Deferred Revenue
YoY Change
Short-Term Debt $81.22K
YoY Change -72.73%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.297M $3.024M
YoY Change 53.87% 71.3%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.297M $3.024M
Total Long-Term Liabilities $0.00
Total Liabilities $3.297M $3.024M
YoY Change 53.87% 71.3%
SHAREHOLDERS EQUITY
Retained Earnings -$7.655M -$7.327M
YoY Change 21.97% 29.05%
Common Stock $11.35K $11.35K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.194M -$2.884M
YoY Change
Total Liabilities & Shareholders Equity $103.8K $139.7K
YoY Change -59.69% -69.54%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$328.2K -$278.2K
YoY Change -45.17% -25.36%
Depreciation, Depletion And Amortization $907.00 $907.00
YoY Change 0.0% 0.0%
Cash From Operating Activities -$209.2K
YoY Change -60.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 245.9K
YoY Change -46.88%
NET CHANGE
Cash From Operating Activities -209.2K
Cash From Investing Activities
Cash From Financing Activities 245.9K
Net Change In Cash 36.70K
YoY Change -161.18%
FREE CASH FLOW
Cash From Operating Activities -$209.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11346535 shares
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
CY2024Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
usd
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56257
dei Entity Registrant Name
EntityRegistrantName
ACCUSTEM SCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-3774438
dei Entity Address Address Line1
EntityAddressAddressLine1
5 Penn Plaza
dei Entity Address Address Line2
EntityAddressAddressLine2
19th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
#1954 New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10001
dei City Area Code
CityAreaCode
00 44
dei Local Phone Number
LocalPhoneNumber
2074952379
dei Security12g Title
Security12gTitle
Common Stock
dei Trading Symbol
TradingSymbol
ACUT
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2023Q4 us-gaap Cash
Cash
21481 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
108368 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
129849 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4048 usd
CY2023Q4 us-gaap Assets
Assets
133897 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
578378 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1454986 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
156434 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
55679 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2245477 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2245477 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11346535 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11346535 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11346535 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11346535 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
11346 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4399019 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6521945 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2111580 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
133897 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30177 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1175920 usd
us-gaap Operating Expenses
OperatingExpenses
1206097 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1206097 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1206097 usd
us-gaap Net Income Loss
NetIncomeLoss
-1206097 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11346535 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11346535 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11346535 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11346535 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11346535 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11346535 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11346535 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11346535 shares
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2620014 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13933 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-278225 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2884306 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-946682 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12626 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-372756 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1306812 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2111580 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32101 usd
us-gaap Net Income Loss
NetIncomeLoss
-804827 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2884306 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-139550 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-139550 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
38835 usd
us-gaap Net Income Loss
NetIncomeLoss
-1206097 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1306812 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1306812 usd
us-gaap Net Income Loss
NetIncomeLoss
-1206097 usd
us-gaap Depreciation
Depreciation
1815 usd
us-gaap Share Based Compensation
ShareBasedCompensation
38835 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-209293 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-29603 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
70935 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
33000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-146383 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-968999 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
537925 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
182253 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
355672 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-613327 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
733978 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
120651 usd
us-gaap Notes Issued1
NotesIssued1
372879 usd
us-gaap Interest Paid Net
InterestPaidNet
702 usd
us-gaap Net Income Loss
NetIncomeLoss
-804827 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7326772 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zVWPUsz6Ift2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zv5vr1xV4Gr5">Use of Estimates </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q2 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10999 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10999 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8766 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6951 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2233 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4048 usd
CY2024Q2 us-gaap Depreciation
Depreciation
907 usd
CY2024Q2 ACUT Accrued Legal Expenses Current
AccruedLegalExpensesCurrent
146594 usd
CY2023Q4 ACUT Accrued Legal Expenses Current
AccruedLegalExpensesCurrent
146594 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8304 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9840 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
154898 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
156434 usd
CY2024Q2 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
8494 usd
us-gaap Foreign Currency Translation Adjustment Description
ForeignCurrencyTranslationAdjustmentDescription
converted from EUROS to USD using exchange rate of €1:$1.076247
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-278225 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-372756 usd
us-gaap Net Income Loss
NetIncomeLoss
-804827 usd
us-gaap Net Income Loss
NetIncomeLoss
-1206097 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-278225 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-372756 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-804827 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1206097 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11346535 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11346535 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
640861 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1621015 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
640861 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1621015 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1621015 shares
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13933 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12626 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32101 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38835 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0180 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5343 pure
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
790198 usd
CY2024Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0 shares

Files In Submission

Name View Source Status
0001493152-24-036330-index-headers.html Edgar Link pending
0001493152-24-036330-index.html Edgar Link pending
0001493152-24-036330.txt Edgar Link pending
0001493152-24-036330-xbrl.zip Edgar Link pending
acut-20240630.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
acut-20240630_def.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
acut-20240630_cal.xml Edgar Link unprocessable
acut-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
acut-20240630_lab.xml Edgar Link unprocessable